• ISSN(Print): 2789-4355
    ISSN(Online): 2958-0358
  • editor.hmdj@hitec-ims.edu.pk
    051- 4908582
  • HITEC-IMS, HIT, Taxila Cantt,
    Punjab, Pakistan
  • Submit Manuscript
HITEC Medical & Dental Journal (HMDJ) Submit Manuscript
Efficacy Of The Combination Of Daclatasvir And Sofosbuvir For The Management Of Hcv Genotype 3 Patients

Authors

Sana Tahir Virk
Fellow, Infectious diseases, PIMS
Sadaf Yousaf
Associate consultant gastroenterology, Shifa International Hospital
Kazim Abbas Virk
Assistant Professor Gastroenterology, HBS General Hospital
Zaid Umer
Assistant Professor pulmonology- RMU
Abeer Zafar
Fellow, Infectious diseases, PIMS
Mahwish Ahmad
Assistant Professor Dermatology - HBS General Hospital

Keywords

Daclatasvir, Genotype, Hepatitis C, chronic, Sofosbuvir, Sustained virologic response.

Abstract

Objective:
To determine the frequency of sustained virologic response (SVR) of Daclatasvir (DCV) plus Sofosbuvir (SOV) for the management of HCV genotype 3 infections in non-cirrhotic patients.
Study Design:
Prospective, observational study.
Place and Duration of Study:
Gastroenterology department, Shifa International Hospital Islamabad, 06 months (May to November 2019).
Methodology:
Total 75 diagnosed and treatment- naive patients of chronic HCV genotype 3, in whom liver cirrhosis was ruled out by abdominal ultrasound, were included in the study, by non-probability convenience sampling. A combination of DCV (60mg) and SOV(400mg) orally once daily for 12 weeks was given to all and were followed up in the OPD for 12 weeks after treatment. After 12 weeks of completion of treatment, HCV PCR was checked to evaluate the SVR after 12 weeks (SVR-12).
Results:
Out of 75 patients, male patients were 56% while female patients were 44%. The mean age was 48.65 ± 13.72 years. Diabetes mellitus was present in 62.7% of the patients. SVR-12 was achieved in 85.3% which showed insignificant association with gender (p-value 0.916), diabetes mellitus (p-value 0.455) and age (p-value 0.076).
Conclusion:
Achieving an SVR-12 rate of 85.3% depicts that the combination of DCV and SOV is extremely efficient in treating the HCV genotype 3, Its efficacy is consistent across patients, regardless of age, gender, or diabetes mellitus.

How to cite this article

: Virk ST, Yousaf S, Virk KA, Umer Z, Zafar A, Ahmad M. Efficacy of the Combination of Daclatasvir and Sofosbuvir for the Management of HCV Genotype 3 Patients. HMDJ. 2024 Dec; 04(02): 45-49. https://doi.org/10.69884/hmdj.4.2.3963.
DOI: https://doi.org/10.69884/hmdj.4.2.3963

References

  1. Ather HM, Shahid A, Usama M, Amir M, Mahmood A, Waheed U. Efficacy of Velpatasvir and Sofosbuvir combination therapy in chronic HCV patients. Ann Punjab Med Coll. 2023 Jun 30;17(2):179-182. https://doi.org/10.29054/apmc/2023.1283.
  2. Ather HM, Shani I, Aamer M, Mahmood A, Ahmad N. Efficacy of dacaltasvir and sofosbuvir combination therapy in chronic HCV population in private clinic set up. Professional Med J. 2020 Aug 10;27(07):1323-1327. https://doi.org/10.29309/TPMJ/2020.27.08.486.
  3. Habkreo M, Moussa AM, Ngare AA, Kossou A, Saleh TM, Dehainsala M, et al. Evaluation of the strategy and efficacy of treatment of chronic viral hepatitis C with the sofosbuvir/daclatasvir combination in a resourcelimited country. Open J Gastroenterol. 2024 Jul 26;14(7):233-240. https://doi.org/10.4236/ojgas.2024.147026.
  4. Mei YY, Chen YM, Wu YK, Zhang XH, Xu WX. Efficacy and safety of sofosbuvir-based direct-acting antiviral agents treatment for patients with genotype 3/6 hepatitis C virus infection. Can J Gastroenterol Hepatol. 2020;2020(1):8872120. https://doi.org/10.1155/2020/8872120
  5. Butt Z, Shah SM. Daclatasvir plus Sofosbuvir with or without ribavirin in patients with chronic Hepatitis C genotype 3a in Pakistani population-a real world experience. Pak J Med Sci. 2019 Mar;35(2):409. https://doi.org/10.12669/pjms.35.2.637
  6. Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). J Hepatol. 2016 May;63(5):1430-1441. http://onlinelibrary.wiley.com/doi/10.1002/hep.28473/suppinfo.
  7. Ullah Z, Khan SZ, Lodhi H, Khan H, Hidayat R, Ahmed M. Efficacy of sofosbuvir and daclatasvir in achieving the end treatment response and sustained viral response in patients infected with hepatitis C virus genotype 3. Pak Armed Forces Med J. 2022 Jun 27;72(3):1074-1077.https://doi.org/10.51253/pafmj.v72i3.4470
  8. Pellicelli A, Messina V, Giannelli V, Distefano M, Palitti VP, Vignally P, et al. High efficacy and safety of flat-dose ribavirin plus sofosbuvir/daclatasvir in genotype 3 cirrhotic patients. J Gut Liver. 2019 Aug 14;14(3):357. https://doi.org/10.5009/gnl18269
  9. Butt N, Khan MA, Akbar A. Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An experience of tertiary care hospital in Karachi. Pak J Med Sci. 2021 Nov;37(7):2014. https://doi.org/10.12669/pjms.37.7.4627
  10. Hezode C, Leroy V, Rosa I, Roudot-Thoraval F, Pawlotsky JM, De Ledinghen V, et al.Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus genotype 3 infection. J Hepatol. 2017;1(66):S299-300.
  11. Siddique H, Tariq SS, Asghar SP, Fahim MF. Meta-analysis of the effectiveness of Sofosbuvir-based regimens in treating hepatitis C genotype 3. J Bahria Univ Med Dental Coll. 2024 Jul 23;14(03):217-223. https://doi.org/10.51985/JBUMDC2024319.
  12. Ahmed A, Rafique I, Sana F, Khurshid S, Yousaf S, Khan A. DaclatasvirSofosbuvir combination therapy with or without Ribavirin for hepatitis-C virus infection: an experience from a tertiary care hospital, Pakistan. Pak Armed Forces Med J. 2023; 73(5): 1517-1521.https://doi.org/10.51253/pafmj.v73i5.8446.
  13. Mushtaq S, Akhter TS, Khan A, Sohail A, Khan A, Manzoor S. Efficacy and safety of generic sofosbuvir plus daclatasvir and sofosbuvir/velpatasvir in HCV genotype 3-infected patients: real-world outcomes from Pakistan. Frontiers Pharmacol. 2020 Sep 2;11:550205. doi.org/10.3389/fphar.2020.550205
  14. Margusino-Framiñán L, Cid-Silva P, Mena-de-Cea Á, Rodríguez-Osorio I, Pernas-Souto B, Delgado-Blanco M, et al. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice. Rev Esp Quimioter. 2019 Apr;32(2):137
  15. Duerr M, Schrezenmeier EV, Lehner LJ, Bergfeld L, Glander P, Marticorena Garcia SR, et al. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients. BMC Nephrol. 2019 Dec;20:1. doi.org/10.1186/s12882-019-1218-0
  16. Farrag AN, Kamel AM. Efficacy of 8-week daclatasvir-sofosbuvir regimen in chronic hepatitis C: a systematic review and meta-analysis. Virol J. 2024 Nov 4;21(1):275. doi.org/10.1186/s12985-024-02544-2
  17. Ziauddin IU, Zeb S, Zia S, Khan D, Abbas M. Combination of Sofosbuvir and Daclatsvir in the treatment of hepatitis C genotype 2 and genotype 3. Med Forum. 2021;32(4):20-23.

All Volumes

PDF
HMDJ © 2024 All Right Reserved || Powered By IT Department